Selexipag Accord for Pulmonary arterial hypertension
Quick answer: Selexipag Accord is used for Pulmonary arterial hypertension as part of a selective prostacyclin (ip) receptor agonist treatment regimen. Selexipag and its active metabolite selectively activate the IP prostacyclin receptor causing pulmonary vasodilation and antiproliferative effects The specific dosing for Pulmonary arterial hypertension is determined by your prescriber based on individual factors.
Why is Selexipag Accord used for Pulmonary arterial hypertension?
Selexipag Accord belongs to the Selective prostacyclin (IP) receptor agonist class. Selexipag and its active metabolite selectively activate the IP prostacyclin receptor causing pulmonary vasodilation and antiproliferative effects This action makes it useful for treating or managing Pulmonary arterial hypertension in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Selexipag Accord is the right choice for a specific patient depends on the type and severity of Pulmonary arterial hypertension, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Pulmonary arterial hypertension
Common adult dosing range: 200 mcg twice daily, titrated up to 1600 mcg twice daily. The actual dose for Pulmonary arterial hypertension depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Selexipag Accord medicine page.
What to expect
Selexipag Accord treatment for Pulmonary arterial hypertension typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Pulmonary arterial hypertension
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Selexipag Accord is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Selective prostacyclin (IP) receptor agonist for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Selexipag Accord
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Selexipag Accord full prescribing information · All Selective prostacyclin (IP) receptor agonist alternatives
Frequently asked questions
How effective is Selexipag Accord for Pulmonary arterial hypertension?
Effectiveness varies by individual response, dose, and severity. Selexipag Accord is one of several treatment options for Pulmonary arterial hypertension, supported by clinical evidence within the selective prostacyclin (ip) receptor agonist class. Discuss expected response with your prescriber.
How long do I need to take Selexipag Accord for Pulmonary arterial hypertension?
Treatment duration depends on the nature of Pulmonary arterial hypertension — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Selexipag Accord when used for Pulmonary arterial hypertension?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Selexipag Accord for Pulmonary arterial hypertension?
Yes. Multiple medicines and non-drug options exist for Pulmonary arterial hypertension. Alternatives within the selective prostacyclin (ip) receptor agonist class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.